NCT02842827View on ClinicalTrials.gov

A Study of Bomedemstat (IMG-7289/MK-3543) With and Without ATRA, in Participants With Advanced Myeloid Malignancies (IMG-7289-CTP-101/MK-3543-001)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

October 6, 2016

Primary Completion Date

October 30, 2018

Study Completion Date

October 30, 2018

Conditions
Acute Myeloid LeukemiaMyelodysplastic Syndrome
Interventions
DRUG

bomedemstat

oral administration

DRUG

tretinoin

oral administration

Trial Locations (1)

Unknown

Royal Adelaide Hospital, Adelaide

All Listed Sponsors
lead

Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)

INDUSTRY

NCT02842827 - A Study of Bomedemstat (IMG-7289/MK-3543) With and Without ATRA, in Participants With Advanced Myeloid Malignancies (IMG-7289-CTP-101/MK-3543-001) | Biotech Hunter | Biotech Hunter